Comparative Efficacy, Safety and Tolerability of Inj. Cefozopran Hydrochloride and Inj. Cefpirome Sulphate in the Treatment of Community Acquired Pneumonia - An Open-label Study.

Ranbaxy Research Laboratories0 个研究点目标入组 100 人开始时间: 待定最近更新: 2021年11月24日

试验速览

阶段: 3 期
状态: 已完成
发起方
入组人数: 100

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

入选标准

•1.Subjects who have given written informed consent to participate in this study
•2.Subjects of either sex, aged greater than or equal to 18 years, with diagnosis of community acquired pneumonia requiring hospitalization. The reason for hospitalization will include two or more of the following
•a.Elderly (greater than 60 years of age)b.Tachypnoea (respiratory rate greater than or equal to 30 per min)
•c.Tachycardia (pulse rate greater than 140 per min)
•d.Hypotension (systolic blood pressure less than 90 mm Hg)
•e.Hypoxemia (arterial Po2 less than 60 mm Hg while subject is breathing on room air or oxygen saturation less than 90 percent)
•f. Acute alteration of mental status
•The diagnosis of CAP will be made on the basis of clinical and radiological criteria as given below:
•A.Clinical Criteria
•A subject should have at least one of the following signs and symptoms
•a.Cough with production of purulent sputum
•b.Fever, defined as body temperature more then 38 degree C (100.4 degree F)taken orally.
•c.Dyspnoea or tachypnoea (respiratory rate more then or equal to 30 per min
•d.Chest pain
•e.Clinical findings on chest examination of pulmonary consolidation (dullness on percussion, bronchial breath sounds or egophony)B.Radiological Criteria
•Chest radiograph should show the presence of new infiltrates in a lobar or multi lobar distribution characteristic of bacterial pneumonia within 48 hours prior to initiation of study treatment

排除标准

•1.Subjects with history of hypersensitivity to Cefozopran, Cefpirome, Cefpodoxime or their excipients, penicillins, cephalosporins or other beta-lactam class of antibiotics.
•Excipients of Cefozopran are Sodium carbonate anhydrous and sodium chloride; Cefpirome: Sodium carbonate anhydrous.
•Excipients of Cefpodoxime are Carboxymethyl cellulose calcium, hydroxypropylcellulose, sodium lauryl sulphate, lactose, magnesium stearate, FD&C Yellow No. 6, FD&C Red No. 40
•2.Subjects who are diagnosed with hospital acquired pneumonia (onset of pneumonia more then or equal to 48 hours after admission to a hospital), atypical pneumonia, viral pneumonia or aspiration pneumonia
•3.Subjects with known bronchial obstruction or a history of post-obstructive pneumonia.
•4.Subjects with history of allergic bronchitis, hives, rashes, bronchial asthma, bronchiectasis, cystic fibrosis, or lung abscess, known or suspected active pulmonary tuberculosis, primary lung cancer or another malignancy metastatic to lungs.
•5.Subjects on chronic immunosuppressive therapy, including use of high dose corticosteroids (more then or equal to 40 mg prednisolone daily or equivalent), or history of acquired immunodeficiency syndrome (AIDS)
•6.Subjects with history of vitamin K deficiency or conditions predisposing to vitamin K deficiency such as subjects with poor oral intake or on parenteral nutrition or having malabsorption syndrome.
•7.Subjects with adult respiratory distress syndrome (ARDS), meningitis, septic shock, extensive bilateral consolidation, empyema or large pleural effusion or severe CAP requiring ventilator support.
•8.Subjects with abnormal laboratory values at screening: SGOT or AST or SGPT or ALT or alkaline phosphatase or serum bilirubin more then 2 times upper limit of normal or total leukocyte count less then 3500 per mm cube
•9.Subjects with creatinine clearance of less then or equal to 30 mL per min or those requiring peritoneal dialysis or hemodialysis
•10.Subjects who have received antibiotic treatment for more then 24 hrs during the 72 hours prior to enrollment in the study
•11.Subjects with significant disease(s) or disorder(s) other than CAP that in the opinion of the investigator may (i) put the subject at risk because of participation in the study (ii) interfere with the study evaluations or (iii) cause concern regarding subjectâ??s ability to participate in the study
•12.Pregnant or breast-feeding women or women of child-bearing potential not willing to use medically acceptable methods of contraception or women with positive urine pregnancy test at screening
•13.Subjects with a history of substance abuse as per DSM IV criteria
•14.Subjects unwilling or unable to comply with the study procedures
•15.Subjects who have participated in another investigational study in the previous 3 months prior to entry in this study

研究者

发起方

Ranbaxy Research Laboratories

相似试验

已完成

3 期

Cefozopran injection in treatment of complicated urinary tract infection and pyelonephritis

CTRI/2013/02/003340Ranbaxy Laboratories Ltd100

尚未招募

不适用

Comparison of two inject able iron preparations for treatment of iron deficiency anemia in pregnancy

CTRI/2019/02/017553Department of Obstetrics and Gynecology

已完成

3 期

A clinical trial to study the effects of Olopatadine Extended Release Tablets, in patients with seasonal allergic rhinitis.

CTRI/2010/091/001058Ranbaxy Laboratories Ltd200

已完成

2 期

Comparative study of Silver sulfadiazine cream (nanonized)and Silverex cream in burns wounds

CTRI/2011/09/002030Ranbaxy Laboratories Ltd36

已完成

3 期

anonized Silver Sulfadiazine Cream in prevention of Infections in Burn wounds

CTRI/2014/11/005188Sun Pharmaceutical Industries Limited250